Literature DB >> 30719842

Isolated vocal cord paralysis in two siblings with compound heterozygous variants in MUSK: Expanding the phenotypic spectrum.

Chaya Murali1, Dong Li2, Katheryn Grand1, Hakon Hakonarson2, Elizabeth Bhoj1,2.   

Abstract

The congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders caused by perturbations in signal transduction at the neuromuscular junction. Defects in muscle, skeletal, receptor tyrosine kinase (MuSK) cause two distinct phenotypes: fetal akinesia with multiple congenital anomalies (Fetal akinesia deformation sequence [MIM:208150]) and early onset congenital myasthenia (myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency [MIM:616325]). Myasthenia due to MuSK deficiency has variable clinical features, ranging from a milder presentation of isolated late-onset proximal muscle weakness; to a severe presentation of prenatal-onset diffuse weakness, ophthalmoplegia, respiratory failure, and vocal cord paralysis (VCP). Here, we propose to expand the phenotypic spectrum for MuSK deficiency to include isolated VCP with the absence of other classical myasthenic symptoms. We evaluated two brothers who presented in the neonatal period with respiratory failure secondary to isolated VCP. Research-based exome sequencing revealed biallelic likely pathogenic variants in MUSK (MIM:601296). Both children had normal gross motor and fine motor development. One brother had speech delay, likely due to a combination of tracheostomy status and ankyloglossia. This case report suggests that CMS should be on the differential diagnosis for familial recurrence of VCP.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Dok-7 deficiency; MuSK deficiency; congenital myasthenic syndromes; phenotypic expansion; vocal cord paralysis

Mesh:

Substances:

Year:  2019        PMID: 30719842      PMCID: PMC6924566          DOI: 10.1002/ajmg.a.61060

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  17 in total

1.  A severe congenital myasthenic syndrome with "dropped head" caused by novel MUSK mutations.

Authors:  Miriam L Giarrana; Pascal Joset; Heinrich Sticht; Stephanie Robb; Katharina Steindl; Anita Rauch; Andrea Klein
Journal:  Muscle Nerve       Date:  2015-06-01       Impact factor: 3.217

2.  Clinical utility of whole-exome sequencing in rare diseases: Galactosialidosis.

Authors:  Carlos E Prada; Claudia Gonzaga-Jauregui; Rebecca Tannenbaum; Samantha Penney; James R Lupski; Robert J Hopkin; V Reid Sutton
Journal:  Eur J Med Genet       Date:  2014-04-24       Impact factor: 2.708

3.  Two cases of congenital myasthenic syndrome with vocal cord paralysis.

Authors:  Rashid Al-Shahoumi; Lauren I Brady; Jeremy Schwartzentruber; Mark A Tarnopolsky
Journal:  Neurology       Date:  2015-02-18       Impact factor: 9.910

4.  Phenotypic expansion of TBX4 mutations to include acinar dysplasia of the lungs.

Authors:  Przemyslaw Szafranski; Zeynep H Coban-Akdemir; Rosemarie Rupps; Serge Grazioli; David Wensley; Shalini N Jhangiani; Edwina Popek; Anna F Lee; James R Lupski; Cornelius F Boerkoel; Paweł Stankiewicz
Journal:  Am J Med Genet A       Date:  2016-07-04       Impact factor: 2.802

Review 5.  Limb-girdle congenital myasthenic syndrome in a Chinese family with novel mutations in MUSK gene and literature review.

Authors:  Xinghua Luan; Wotu Tian; Li Cao
Journal:  Clin Neurol Neurosurg       Date:  2016-08-22       Impact factor: 1.876

Review 6.  Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.

Authors:  Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Steven M Sine
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

7.  Congenital stridor with feeding difficulty as a presenting symptom of Dok7 congenital myasthenic syndrome.

Authors:  Chris G Jephson; Nikki A Mills; Matthew C Pitt; David Beeson; Annie Aloysius; Francesco Muntoni; Stephanie A Robb; C Martin Bailey
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2010-06-15       Impact factor: 1.675

8.  Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction.

Authors:  Ricardo A Maselli; Juan Arredondo; Orla Cagney; Jarae J Ng; Jennifer A Anderson; Colette Williams; Bae J Gerke; Betty Soliven; Robert L Wollmann
Journal:  Hum Mol Genet       Date:  2010-04-06       Impact factor: 6.150

9.  A mutation causes MuSK reduced sensitivity to agrin and congenital myasthenia.

Authors:  Asma Ben Ammar; Payam Soltanzadeh; Stéphanie Bauché; Pascale Richard; Evelyne Goillot; Ruth Herbst; Karen Gaudon; Caroline Huzé; Laurent Schaeffer; Yuji Yamanashi; Osamu Higuchi; Antoine Taly; Jeanine Koenig; Jean-Paul Leroy; Fayçal Hentati; Hossein Najmabadi; Kimia Kahrizi; Manouchehr Ilkhani; Michel Fardeau; Bruno Eymard; Daniel Hantaï
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

10.  Expansion of phenotypic spectrum of MYO15A pathogenic variants to include postlingual onset of progressive partial deafness.

Authors:  Mun Young Chang; Chung Lee; Jin Hee Han; Min Young Kim; Hye-Rim Park; Nayoung Kim; Woong-Yang Park; Doo Yi Oh; Byung Yoon Choi
Journal:  BMC Med Genet       Date:  2018-02-27       Impact factor: 2.103

View more
  3 in total

Review 1.  The congenital myasthenic syndromes: expanding genetic and phenotypic spectrums and refining treatment strategies.

Authors:  An E Vanhaesebrouck; David Beeson
Journal:  Curr Opin Neurol       Date:  2019-10       Impact factor: 5.710

2.  Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure.

Authors:  Pedro M Rodríguez Cruz; Judith Cossins; Jonathan Cheung; Susan Maxwell; Sandeep Jayawant; Ruth Herbst; Dominic Waithe; Alexandr P Kornev; Jacqueline Palace; David Beeson
Journal:  Hum Mutat       Date:  2019-11-25       Impact factor: 4.878

3.  Congenital Vocal Cord Paralysis and Late-Onset Limb-Girdle Weakness in MuSK-Congenital Myasthenic Syndrome.

Authors:  Marcus V Pinto; Jacqui-Lyn Saw; Margherita Milone
Journal:  Front Neurol       Date:  2019-12-20       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.